P.719 NAPHYRONE – PHARMACOKINETICS AND BEHAVIOURAL PROFILE IN WISTAR RAT

Olejíková Lucie, Štefková Kristýa, Šíchová Klára, Dada Hyek, Lhotková Eva, Piterová Nikola, Páleíček Toáš

National Institute of Mental Health, Klecany, Czech Republic NAPHYRONE METHODS

Naphyrone (naphthylpyrovalerone, O-2482, Energy 1), from the Naphyrone was administered subcutaneously to Wistar rats in a single dose of 5 cathinones group, is a drug derived from pyrovalerone that acts as a triple mg/kg, 10 mg/kg and 20 mg/kg. Open field test was performed in an empty black reuptake inhibitor, producing stimulant effects similar to cocaine, MDMA square arena (68 c × 68 c × 30 c). Rats were placed individually into the center of or amphetamines and has been reported as a novel psychoactive the arena 5 or 40 i after the drug administration (testing-onset) and their behavior was recorded for 30 i. Examined parameters were trajectory length, its spatial substance (NPS). characteristic (thigmotaxis and time spent in the center of the arena). Further the prepulse inhibition (PPI) of acoustic startle reaction (ASR) were determined in this study. Pharmacokinetic profile was analyzed using gas chromatography-mass spectrometry (GCMS). To simulate effects of crowded conditions, body temperature was monitored in animals housed in groups versus individually. Data were analyzed using factorial Analysis of Variance and independent t-tests.

RESULTS

LOCOMOTION PREPULSE INHIBITION OF ACOUSTIC STARTLE

REACTION

lenght (m) Trajectory

Fig. 1: The effect of naphyrone on total locomotion 15 and 60 min after administration. Data are Fig. 3: The effect of naphyrone on prepulse inhibition (PPI) of acoustic startle reaction (ASR). PPI presented as mean±SEM. * p<0.05, ** p<0.01 and *** p<0.001 from the control group, n=10. was not disrupted by any dose of naphyrone. Data are presented as mean ± SEM, n=10.

PHARMACOKINETICS

Naphyrone 10 mg/kg (n=10) 2500 control naphyrone 5 mg/kg naphyrone 10 mg/kg naphyrone 20 mg/kg

Brain (ng/g) Fig. 2: Examples of characteristic trajectories. Each trajectory image represents characteristic /g) 2000

ng Serum (ng/ml) trajectory of one animal (treated with either saline, naphyrone 5, 10 or 20 mg/kg) within the

whole length of measurement (30 min). /ml;

ng 1500 ANXIETY 1000

500 Mean concentartion (

0 0 1 2 3 4 5 6 7 8

(%) Time after administration (hours)

Fig. 5: Mean concentration of naphyrone in serum (ng/ml) and brain (ng/g) over eight hours after subcutaneous administration of naphyrone 10 mg/kg. Symbols are presented as mean ± SD,

Thigmotaxis n=10. Time(s) Center in

CONCLUSIONS

Fig. 4: The effect of naphyrone on time spent in the center of the arena. Data are presented as mean ± SEM. *** p<0.001 from the control group, n=10. • Naphyrone increased locomotion in OFT • Sensorimotor gating is not disrupted by naphyrone ACKNOWLEDGEMENTS • Naphyrone (20 mg/kg) decreased anxiety level This poster was supported by projects VI20172020056, GACR no.: 18-16218S, MH Serum and brain levels of naphyrone peaked at CZ—DRO (NIMH-CZ, 00023752), grant LO1611 from the MEYS CR under the NPU I • program, PROGRES Q35 and 260388/SVV/2018. approximately 30 min after administration